Maccura Biotechnology Co Ltd

Maccura Biotechnology announced on September 1 that as of August 31, 2026, the company had repurchased 570,000 shares, accounting for 0.0939% of total share capital, at an average price of 8.82 yuan per share, with a total payment of 5.01 million yuan. In the first half of 2026, Maccura Biotechnology achieved revenue of 1.034 billion yuan and net profit attributable to the parent of 34.26 million yuan.

Maccura Biotechnology announced its first share buyback after the market closed on July 22, following three consecutive trading days of price declines. The company repurchased 88,800 shares through centralized bidding, accounting for 0.0147% of its total share capital. The average transaction price was 8.78 yuan per share, with a high of 8.88 yuan and a low of 8.67 yuan, for a total payment of approximately 779,300 yuan. According to a previous announcement, the buyback plan was approved by the board of directors on June 18, 2026, and by the extraordinary general meeting on July 6, 2026. The company plans to use its own funds to repurchase A-shares through centralized bidding for cancellation and reduction of registered capital. The total buyback amount will be no less than 50 million yuan and no more than 100 million yuan, with a maximum repurchase price of 14.66 yuan per share. The implementation period is within 12 months from the date of approval by the general meeting. Maccura Biotechnology is a Chinese high-tech enterprise focusing on in-vitro diagnostics, headquartered in Chengdu, Sichuan.